Eastling Thomas Wilson 4
4 · GYRE THERAPEUTICS, INC. · Filed Apr 18, 2025
Insider Transaction Report
Form 4
Eastling Thomas Wilson
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-04-16−15,000→ 299,652 totalExercise: $6.93Exp: 2033-10-31→ Common Stock (15,000 underlying) - Exercise/Conversion
Common Stock
2025-04-16$6.93/sh+15,000$103,950→ 15,000 total
Footnotes (1)
- [F1]These options are vested in full.